KIG
INO icon

Kessler Investment Group’s Inovio Pharmaceuticals INO Stock Holding History

Kessler Investment Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45
Closed -$1K – 178
2022
Q3 		$1K Hold
45
– – ﹤0.01% 175
2022
Q2 		$1K Hold
45
– – ﹤0.01% 164
2022
Q1 		$2K Hold
45
– – ﹤0.01% 168
2021
Q4 		$3K Buy
+45
New +$3.6K ﹤0.01% 162

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Kessler Investment Group's INO Position: Q4 2022 in Review

Kessler Investment Group sold out of Inovio Pharmaceuticals (INO) in Q4 2022, closing a stake of 45 shares — an estimated $1K sold.

Kessler Investment Group first reported a position in INO in Q4 2021 and held it in 4 quarters. The position peaked at $3K in Q4 2021. 183 funds tracked by Wall St. Rank hold INO as of Q4 2022.

  • Kessler Investment Group reported no remaining Inovio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Kessler Investment Group sold 45 Inovio Pharmaceuticals shares in Q4 2022, an estimated $1K.
  • Kessler Investment Group first reported a position in Inovio Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Kessler Investment Group's Inovio Pharmaceuticals position peaked at $3K in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2022.

Based on Kessler Investment Group's 13F filing for Q4 2022, filed 31 Jan 2023.